+1,852.3%
STX vs GSK
+97.7%
+1,754.6%
-57.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | -1.6% | +2.6% | +1.5% |
| 7D | -4.4% | -4.7% | +0.4% | -3.2% |
| 30D | -22.8% | -4.7% | -18.1% | -22.0% |
| 3M | -37.3% | -8.8% | -28.6% | -36.1% |
| 6M | -28.8% | -4.6% | -24.2% | -29.2% |
| YTD | +89.9% | +1.0% | +89.0% | +83.3% |
| 1Y | +102.4% | +6.9% | +95.5% | +91.0% |
| 3Y | +629.4% | +52.5% | +576.9% | +478.0% |
| 5Y | +496.2% | +40.3% | +455.9% | +381.0% |
| All | +1,852.3% | +97.7% | +1,754.6% | +1,188.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling